右みぎ旋安非ひ他た命いのち

右みぎ旋安非ひ他た命いのち
INN： Dexamfetamine
臨床りんしょう資料しりょう
AHFS/Drugs.com	Monograph
MedlinePlus	a605027
核かく准じゅん狀況じょうきょう	美よし FDA: Dextroamphetamine;
懷ふところ孕分級きゅう	澳: B3 ; ;
依賴いらい性せい	生理せいり依よ赖：无; 精神せいしん依よ赖：中なか
成なり癮性	中なか
给药途と径みち	口くち服ふく
ATC碼	N06BA02 (WHO) ;
法律ほうりつ規範きはん狀態じょうたい
法律ほうりつ規範きはん	澳：受管控ひかえ（S8）; 加か：Schedule I; 德とく：Anlage III; 英えい：Class B; 美よし：附ふ表ひょうII;
藥物やくぶつ動力どうりょく學がく數かず據よりどころ
生物せいぶつ利用りよう度ど	Oral 75–100%
血漿けっしょう蛋白たんぱく結合けつごう率りつ	15–40%
药物代だい谢	CYP2D6，多た巴ともえ胺βべーた羟化酶， FMO3（英えい语：Flavin-containing monooxygenase）
藥效やっこう起おこり始はじめ時間じかん（英えい语：Onset of action）	IR服用ふくよう：0.5至いたり1.5小しょう时; XR服用ふくよう：1.5至いたり2小しょう时
生物せいぶつ半はん衰おとろえ期き	9至いたり11小しょう时; 不同ふどう的てきPH值：8至いたり31小しょう时
作用さよう時間じかん	IR服用ふくよう：3至いたり7小しょう时; XR服用ふくよう：12小しょう时
排泄はいせつ途と徑みち	肾（45%）；取と决于尿にょう液えき的てきpH值
识别信しん息いき
	IUPAC命名めいめい法ほう (2S)-1-phenylpropan-2-amine; ;
CAS号ごう	51-64-9
PubChem CID	5826;
IUPHAR/BPS	2147;
DrugBank	DB01576 ;
ChemSpider	5621 ;
UNII	TZ47U051FI;
KEGG	D03740 ;
ChEBI	CHEBI:4469 ;
ChEMBL	ChEMBL612 ;
CompTox Dashboard（英えい语：CompTox Chemicals Dashboard） (EPA)	DTXSID8022907 ;
ECHA InfoCard	100.000.103
化学かがく信しん息いき
化学かがく式しき	C9H13N
摩ま尔质量りょう	135.20622
3D模型もけい（JSmol（英えい语：JSmol））	交互こうご式しき图像;
密度みつど	0.913 g/cm3
沸点ふってん	201.5 °C（394.7 °F）
水溶すいよう性せい	20 mg/mL (20 °C)
	SMILES C[C@@H](Cc1ccccc1)N;
	InChI InChI=InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1 ; Key:KWTSXDURSIMDCE-QMMMGPOBSA-N ;

右みぎ旋安非ひ他た命いのち（英語えいご：Dextroamphetamine）^{[注ちゅう 1]}是ぜ强力きょうりょく中樞ちゅうすう神經しんけい兴奋剂，也是苯丙胺（“安やす非ひ他た命いのち”）的てき对映异构体たい，是ぜ注意ちゅうい力不足ちからぶそく過か動どう症しょう（ADHD）和わ發作ほっさ性せい嗜睡病びょう的てき处方药。^[10]此外，它也被ひ用作ようさく提つつみ升ます运动员能力りょく的てき兴奋剂，也是一いち种益えき智さとし药，同どう时人们在享とおる乐时也将其用作さく春はる药和わ产生欣快きんかい感かん的てき药。此外，空そら军也将はた右みぎ旋安非ひ他た命いのち广泛用作ようさく“抗こう睡ねむ丸まる”，在ざい诸如夜よる间轰炸之类的容易ようい疲つかれ倦的任にん务中使用しよう。第だい二に次じ世界せかい大だい战期き间，该药物ぶつ也被用よう来らい治ち疗疲倦。

脚注きゃくちゅう[编辑]

^ 其他英文えいぶん名称めいしょう：dexamphetamine （AAN（英えい语：Australian Approved Name））、dexamfetamine （国くに际非专利药品名称めいしょう和わBAN（英えい语：British Approved Name））、(S)-amphetamine、(+)-amphetamine、D-amphetamine。

参考さんこう资料[编辑]

^ Dextromphetamine. DrugBank. [2013-11-05]. （原始げんし内容ないよう存そん档于2019-08-06）. |section=被ひ忽ゆるがせ略りゃく (帮助)
^ Green-Hernandez, Carol; Singleton, Joanne K.; Aronzon, Daniel Z. Primary Care Pediatrics. Lippincott Williams & Wilkins. 2001-01-01: 243 [2017-05-07]. ISBN 9780781720083. （原始げんし内容ないよう存そん档于2016-05-23）. |quote = Table 21.2 Medications for ADHD ... D-amphetamine ... Onset: 30 min.
^ Dexedrine, ProCentra(dextroamphetamine) dosing, indications, interactions, adverse effects, and more. reference.medscape.com. [2015-10-04]. （原始げんし内容ないよう存そん档于2018-11-06）. Onset of action: 1–1.5 hr
^ ^4.0 ^4.1 ^4.2 Millichap JG. Chapter 9: Medications for ADHD. Millichap JG (编). Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD 2nd. New York, USA: Springer. 2010: 112. ISBN 9781441913968.
Table 9.2 Dextroamphetamine formulations of stimulant medication
Dexedrine [Peak:2–3 h] [Duration:5–6 h] ...
Adderall [Peak:2–3 h] [Duration:5–7 h]
Dexedrine spansules [Peak:7–8 h] [Duration:12 h] ...
Adderall XR [Peak:7–8 h] [Duration:12 h]
Vyvanse [Peak:3–4 h] [Duration:12 h]
^ ^5.0 ^5.1 Brams M, Mao AR, Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgrad. Med. September 2008, 120 (3): 69–88. PMID 18824827. doi:10.3810/pgm.2008.09.1909. Onset of efficacy was earliest for d-MPH-ER at 0.5 hours, followed by d, l-MPH-LA at 1 to 2 hours, MCD at 1.5 hours, d, l-MPH-OR at 1 to 2 hours, MAS-XR at 1.5 to 2 hours, MTS at 2 hours, and LDX at approximately 2 hours. ... MAS-XR, and LDX have a long duration of action at 12 hours postdose
^ Adderall IR Prescribing Information (PDF). United States Food and Drug Administration. Teva Pharmaceuticals USA, Inc.: 1–6. October 2015 [2016-05-18]. （原始げんし内容ないよう存そん档 (PDF)于2018-09-15）.
^ ^7.0 ^7.1 Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. October 2012, 9 (4): 739–752. PMC 3480574 . PMID 23065655. doi:10.1007/s13311-012-0150-9.
^ dextrostat (dextroamphetamine sulfate) tablet [Shire US Inc.]. DailyMed. Wayne, PA: Shire US Inc. August 2006 [2013-11-08]. （原始げんし内容ないよう存そん档于2012-01-13）.
^ Lemke TL, Williams DA, Roche VF, Zito W. Foye's Principles of Medicinal Chemistry 7th. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2013: 648. ISBN 1609133455. Alternatively, direct oxidation of amphetamine by DA βべーた-hydroxylase can afford norephedrine.
^ Dexedrine Prescribing Information (PDF). United States Food and Drug Administration. Amedra Pharmaceuticals LLC: 1–7. February 2015 [2015-09-04]. （原始げんし内容ないよう存そん档 (PDF)于2017-02-17）.

[10] 其他英文えいぶん名称めいしょう：dexamphetamine （AAN（英えい语：Australian Approved Name））、dexamfetamine （国くに际非专利药品名称めいしょう和わBAN（英えい语：British Approved Name））、(S)-amphetamine、(+)-amphetamine、D-amphetamine。

[1] Dextromphetamine. DrugBank. [2013-11-05]. （原始げんし内容ないよう存そん档于2019-08-06）. |section=被ひ忽ゆるがせ略りゃく (帮助)

[2] Green-Hernandez, Carol; Singleton, Joanne K.; Aronzon, Daniel Z. Primary Care Pediatrics. Lippincott Williams & Wilkins. 2001-01-01: 243 [2017-05-07]. ISBN 9780781720083. （原始げんし内容ないよう存そん档于2016-05-23）. |quote = Table 21.2 Medications for ADHD ... D-amphetamine ... Onset: 30 min.

[3] Dexedrine, ProCentra(dextroamphetamine) dosing, indications, interactions, adverse effects, and more. reference.medscape.com. [2015-10-04]. （原始げんし内容ないよう存そん档于2018-11-06）. Onset of action: 1–1.5 hr

[Millichap:_onset,_peak,_and_duration-4] 4.0 ^4.1 ^4.2 Millichap JG. Chapter 9: Medications for ADHD. Millichap JG (编). Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD 2nd. New York, USA: Springer. 2010: 112. ISBN 9781441913968.
Table 9.2 Dextroamphetamine formulations of stimulant medication
Dexedrine [Peak:2–3 h] [Duration:5–6 h] ...
Adderall [Peak:2–3 h] [Duration:5–7 h]
Dexedrine spansules [Peak:7–8 h] [Duration:12 h] ...
Adderall XR [Peak:7–8 h] [Duration:12 h]
Vyvanse [Peak:3–4 h] [Duration:12 h]

[XR_onset-duration-5] 5.0 ^5.1 Brams M, Mao AR, Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgrad. Med. September 2008, 120 (3): 69–88. PMID 18824827. doi:10.3810/pgm.2008.09.1909. Onset of efficacy was earliest for d-MPH-ER at 0.5 hours, followed by d, l-MPH-LA at 1 to 2 hours, MCD at 1.5 hours, d, l-MPH-OR at 1 to 2 hours, MAS-XR at 1.5 to 2 hours, MTS at 2 hours, and LDX at approximately 2 hours. ... MAS-XR, and LDX have a long duration of action at 12 hours postdose

[Adderall_IR-6] Adderall IR Prescribing Information (PDF). United States Food and Drug Administration. Teva Pharmaceuticals USA, Inc.: 1–6. October 2015 [2016-05-18]. （原始げんし内容ないよう存そん档 (PDF)于2018-09-15）.

[Narcolepsy_guide-7] 7.0 ^7.1 Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. October 2012, 9 (4): 739–752. PMC 3480574 . PMID 23065655. doi:10.1007/s13311-012-0150-9.

[8] xtrostat (dextroamphetamine sulfate) tablet [Shire US Inc.]. DailyMed. Wayne, PA: Shire US Inc. August 2006 [2013-11-08]. （原始げんし内容ないよう存そん档于2012-01-13）.

[DBH_ref-9] Lemke TL, Williams DA, Roche VF, Zito W. Foye's Principles of Medicinal Chemistry 7th. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2013: 648. ISBN 1609133455. Alternatively, direct oxidation of amphetamine by DA βべーた-hydroxylase can afford norephedrine.

[Dexedrine-11] Dexedrine Prescribing Information (PDF). United States Food and Drug Administration. Amedra Pharmaceuticals LLC: 1–7. February 2015 [2015-09-04]. （原始げんし内容ないよう存そん档 (PDF)于2017-02-17）.

[1]

[9]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[注ちゅう 1]

[10]